130 related articles for article (PubMed ID: 31967357)
21. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
[TBL] [Abstract][Full Text] [Related]
22. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
Paller C; Pu H; Begemann DE; Wade CA; Hensley PJ; Kyprianou N
Prostate; 2019 Jan; 79(1):31-43. PubMed ID: 30155899
[TBL] [Abstract][Full Text] [Related]
23. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.
Xia X; Huang C; Liao Y; Liu Y; He J; Guo Z; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 May; 38(1):220. PubMed ID: 31126320
[TBL] [Abstract][Full Text] [Related]
25. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
26. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.
Farah E; Li C; Cheng L; Kong Y; Lanman NA; Pascuzzi P; Lorenz GR; Zhang Y; Ahmad N; Li L; Ratliff T; Liu X
J Biol Chem; 2019 May; 294(21):8543-8554. PubMed ID: 30940724
[TBL] [Abstract][Full Text] [Related]
27. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
28. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
29. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
Low JY; Sirajuddin P; Moubarek M; Agarwal S; Rege A; Guner G; Liu H; Yang Z; De Marzo AM; Bieberich C; Laiho M
Prostate; 2019 Dec; 79(16):1837-1851. PubMed ID: 31524299
[TBL] [Abstract][Full Text] [Related]
30. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.
Syvälä H; Pennanen P; Bläuer M; Tammela TL; Murtola TJ
Biochem Biophys Res Commun; 2016 Dec; 481(1-2):46-50. PubMed ID: 27833018
[TBL] [Abstract][Full Text] [Related]
31. Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.
Luo Y; Azad AK; Karanika S; Basourakos SP; Zuo X; Wang J; Yang L; Yang G; Korentzelos D; Yin J; Park S; Zhang P; Campbell JJ; Schall TJ; Cao G; Li L; Thompson TC
Int J Cancer; 2018 May; 142(10):2163-2174. PubMed ID: 29277895
[TBL] [Abstract][Full Text] [Related]
32. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
33. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
34. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
[TBL] [Abstract][Full Text] [Related]
35. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.
Wang Y; Dehigaspitiya DC; Levine PM; Profit AA; Haugbro M; Imberg-Kazdan K; Logan SK; Kirshenbaum K; Garabedian MJ
Cancer Res; 2016 Sep; 76(17):5124-32. PubMed ID: 27488525
[TBL] [Abstract][Full Text] [Related]
36. A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer.
Kurmis AA; Yang F; Welch TR; Nickols NG; Dervan PB
Cancer Res; 2017 May; 77(9):2207-2212. PubMed ID: 28360139
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X
J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652
[TBL] [Abstract][Full Text] [Related]
38. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
Robles AJ; Cai S; Cichewicz RH; Mooberry SL
Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
[TBL] [Abstract][Full Text] [Related]
39. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
40. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
Pilling AB; Hwang C
Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
